$39.14
+2.22%Sep 22, 2026, 23:59 UTC
The University Hospitals Program, under the Council of Universities' Affairs, signed with Novo Nordisk to build earlier-phase clinical trial capability, announced at the Riyadh Global Medical Biotechnology Summit.
Source:Sep 22, 2026, 23:59 UTC
Florida Attorney General James Uthmeier announced a lawsuit in Tampa against insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, pharmacy benefit managers CVS Caremark, Express Scripts and Optum Rx, and rebate aggregators Zinc, Ascent and Emisar, alleging price-fixing, anti-competitive behavior and deceptive trade practices in insulin and diabetes-related drugs.
Sep 22, 2026, 12:00 UTC
Novo Nordisk committed $18 million through 2030 to UNICEF's obesity prevention and treatment program.
Source:Sep 22, 2026, 08:22 UTC
China's Vice Minister of Commerce and International Trade Representative Ling Ji visited Zhongguancun Life Science Park in Beijing and chaired a roundtable with more than 30 foreign-funded enterprises on September 21.
Source:Sep 22, 2026, 03:03 UTC
Novo Nordisk China stated it supports and fully cooperates with Chinese authorities' crackdown on illegal 'reflow drugs' involving semaglutide and will continue advancing its authorized certification channel system.
Source:Sep 21, 2026, 14:45 UTC
Siemens Healthineers and Novo Nordisk announced a partnership to advance the diagnosis and treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
Source:Sep 17, 2026, 16:44 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed Novo Nordisk's hemophilia A therapy.
Source:Sep 17, 2026, 16:44 UTC
Novo Nordisk launched a major cardiometabolic research partnership.
Source:Sep 17, 2026, 11:00 UTC
Orbis Medicines announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases, worth up to USD 1.4 billion.
Sep 16, 2026, 12:00 UTC
Novo Nordisk will use Claude Science to carry out its research and development workflows.
Source:Sep 16, 2026, 12:00 UTC
Novo Nordisk partnered with Anthropic to use Claude to advance drug discovery and development.
Sep 14, 2026, 20:37 UTC
Eli Lilly said its oral weight-loss drug Foundayo has captured more than 30% of new US patients on oral obesity treatments, narrowing Novo Nordisk's early lead with its Wegovy pill.
Source:Sep 14, 2026, 13:14 UTC
Novo Nordisk launched a share buyback program.
Source:Sep 14, 2026, 08:32 UTC
Novo Nordisk announced a brand refresh simplifying its everyday name to "Novo" while keeping the legal name Novo Nordisk A/S, aiming to regain weight-loss drug market share.
Sep 14, 2026, 05:02 UTC
Danish pharmaceutical company Novo Nordisk confirmed it will rebrand by changing its name to "Novo", dropping "Nordisk", and updating its logo and brand tagline, with the changes to be announced before its September 21 capital markets day.
Sep 11, 2026, 04:30 UTC
The High Court in Pretoria dismissed iDexis' application for leave to appeal the interim order barring it from selling compounded semaglutide products, with Judge Petrus van Niekerk calling the application an abuse of process.
Source:Sep 11, 2026, 03:55 UTC
In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.
Source:Sep 7, 2026, 11:44 UTC
Novo Nordisk halted two additional trials of its experimental cardiovascular drug ziltivekimab on Monday, September 7, 2026.
Source:Sep 7, 2026, 11:13 UTC
Novo Nordisk halted two cardiovascular trials (HERMES and ATHENA) of its drug ziltivekimab after a data monitoring committee found they were unlikely to succeed, following the earlier failure of the ZEUS trial.
Source:Sep 7, 2026, 10:00 UTC
Novo Nordisk announced Phase 3 STEP YOUNG clinical data showing that 40.4% of obese children treated with semaglutide plus lifestyle intervention achieved BMI below the obesity threshold.
Sep 5, 2026, 12:00 UTC
Novo Nordisk announced that Andrea Haegebarth will join as Senior Vice President of Global Research, replacing Jacob Petersen, who will become Head of R&D External Innovation, effective 1 October 2026.
Source:Sep 4, 2026, 05:00 UTC
The foundation that controls Novo Nordisk A/S is building a $62 million quantum chip factory in Copenhagen, Denmark.
Source:Sep 2, 2026, 19:15 UTC
Aspen Pharmacare is pursuing the market for generic semaglutide, having obtained regulatory approval in Canada and awaiting registration in about 20 countries including Brazil and South Africa.
Source:Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Aug 28, 2026, 04:00 UTC
Novo Nordisk and Eli Lilly are using court orders and public campaigns to combat counterfeit weight-loss drugs.
Source:Aug 25, 2026, 23:59 UTC
The U.S. federal government, through CMS, announced the BALANCE Model allowing state Medicaid programs to join between May 2026 and January 1, 2027, to negotiate discounted prices for weight-loss drugs, but as of mid-August 2026 no participating states have been named.
Source:Jul 15, 2026, 00:45 UTC
Eli Lilly launched its oral weight-loss drug Foundayo in April 2026.